Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells

CD19-targeted chimeric antigen receptor modified T-cell (CD19 CAR-T cell) immunotherapy has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [2] and non-Hodgkin lymphoma (NHL) [3,4], which led to the approval of tisagenlecleucel (Kymriah ࣨ) and axicabtagene ciloleucel (Yescartaࣨ) by the USA Food and Drug Administration (FDA).

Source: Biology of Blood and Marrow Transplantation - August 12, 2019 Category: Hematology Authors: Ana Cordeiro, Evandro D. Bezerra, Alexandre V. Hirayama, Joshua A. Hill, Vicky Wu, Jenna Voutsinas, Mohamed Sorror, Cameron J. Turtle, David G. Maloney, Merav Bar Source Type: research